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gδ T-cells contribute importantly to tumor immunosur-
veillance and are activated by phosphoantigen inter-
mediates of the mevalonate pathway that are commonly
over-produced in cancer cells. To potentiate this, phos-
phoantigen levels can be boosted using zoledronic acid
(ZA). However, in vivo delivery of ZA to the tumour is
inefficient owing to its poor pharmacokinetic properties.
Here, we set out to develop a gδ T-cell immunotherapy
for epithelial ovarian cancer (EOC) using folate-targeted
liposomal ZA (FT-L-ZA) to improve drug delivery to
tumor cells. Folate receptor-a is over-expressed in EOC.
Peripheral blood mononuclear cells isolated from
healthy donors (n=21) and EOC patients (n=13) were
cultured with ZA, IL-2 and IL-15 for two weeks. gδ T-
cells expanded reproducibly from healthy donors and
patients, the latter having on average a 97-fold expan-
sion. The expanded gδ T-cells expressed low levels of L-
selectin, accompanied by CD45RO, CD27, CD70 and
NKG2D, consistent with a combined central-memory
and effector-memory phenotype, similarly to healthy
controls. To evaluate whether ex-vivo cultured gδ T-
cells from patients with EOC are functionally compe-
tent, we developed an autologous co-cultivation assay
whereby patient-derived gδ T-cells were incubated in-
vitro with primary EOC “tumorspheres”. Twenty-four
hours after incubation of tumorspheres with ZA, L-ZA
or FT-L-ZA, ex-vivo expanded gδ T-cells were added at
a 1:100 ratio. When alone, gδ T-cells destroyed 24.5% of
spheres. Addition of 1µg/ml free ZA sensitized tumor-
spheres to destruction by gδ T-cells (96.2%), but was
relatively ineffective at 0.1µg/ml (26.8%). By contrast,
FT-L-ZA was highly effective at 0.1µg/ml (92.6%) while
non-targeted L-ZA was no better than gδ T-cells only.
Destruction of ZA-sensitized tumorspheres by autolo-
gous gδ T-cells was accompanied by their activation and
production IFN−g (≈ 2000 pg/mL). In the absence of gδ
T-cells, none of these formulations exerted any toxic
effect upon tumorspheres. To model EOC in vivo, SCID
Beige mice were injected intraperitoneally (IP) with luci-
ferase-expressing SKOV-3 cells. Mice (n=5 per group)
were treated IP with 5μg ZA, FT-L-ZA or PBS, followed
by 10E7 ex-vivo expanded gδ T-cells from healthy con-
trols or PBS. Tumour growth was monitored by biolu-
minescence. One week after treatment, mice treated
with gδ T-cells or gδ T-cells and free ZA showed a
tumour reduction of approximately 20%. By contrast,
mice treated with FT-L-ZA followed by gδ T-cells
achieved a tumour reduction of 60-70%. Drugs alone
had no therapeutic effect. We show here proof of con-
cept for a synergistic immunotherapy for EOC whereby
FT-L-ZA can be used to sensitize tumors to gδ T-cells.
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